Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Sep 27;3(2):195-202.
doi: 10.1002/bjs5.97. eCollection 2019 Apr.

Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

F Mercier  1 , F Dagbert  2 , M Pocard  3 , D Goéré  4 , F Quenet  5 , R Wernert  6 , F Dumont  7 , C Brigand  8 , G Passot  1   9 , O Glehen  1   9 ; RENAPE Network
Collaborators, Affiliations
Observational Study

Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

F Mercier et al. BJS Open. .

Abstract

Background: Pseudomyxoma peritonei (PMP) is a rare clinical condition characterized by mucinous ascites, typically related to appendiceal or ovarian tumours. Current standard treatment involves cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), but recurrences occur in 20-30 per cent of patients. The aim of this study was to define the timing and patterns of recurrence to provide a basis for modifying follow-up of these patients.

Methods: This observational study examined a prospectively developed multicentre national database (RENAPE working group) to identify patients with recurrence after optimal CRS and HIPEC for PMP. Postoperative complications, long-term outcomes and potential prognostic factors were evaluated.

Results: Of 1411 patients with proven PMP, 948 were identified who had undergone curative CRS and HIPEC. Among these patients, 229 first recurrences (24·2 per cent) were identified: 196 (20·7 per cent) occurred within the first 5 years (early recurrence) and 30 (3·2 per cent) occurred between 5 and 10 years. Three patients developed a first recurrence more than 10 years after the original treatment. The mean(s.d.) time to first recurrence was 2·36(2·21) years. Preoperative chemotherapy and high-grade pathology were significant factors for early recurrence. Overall survival for the entire group was 77·9 and 63·1 per cent at 5 and 10 years respectively. The principal site of recurrence was the peritoneum.

Conclusion: Recurrence of PMP was rare after 5 years and exceptional after 10 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of patient selection and study groups selected for analysis of pseudomyxoma peritonei (PMP). CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy
Figure 2
Figure 2
Kaplan–Meier curve for overall survival of patients with recurrent pseudomyxoma peritonei following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
Figure 3
Figure 3
Kaplan–Meier curve for overall survival of patients with recurrent pseudomyxoma peritonei following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy, according to site of recurrence. P = 0·570 (log rank test)
Figure 4
Figure 4
Recurrence of pseudomyxoma peritonei according to time of detection after surgery
See this image and copyright information in PMC

References

    1. Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol 2016; 42: 1035–1041. - PubMed
    1. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J et al Long‐term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009; 16: 1903–1911. - PubMed
    1. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 2003; 27: 650–657. - PubMed
    1. Mukherjee A, Parvaiz A, Cecil TD, Moran BJ. Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol 2004; 25: 411–414. - PubMed
    1. de Bree E, Witkamp A, Van De Vijver M, Zoetmulde F. Unusual origins of pseudomyxoma peritonei. J Surg Oncol 2000; 75: 270–274. - PubMed

Publication types

MeSH terms